Adalvo announces the successful multi-country launch of Lisdexamfetamine. To our knowledge, Adalvo was one of the first to introduce this differentiated product in key European markets, showcasing our industry-leading launch capabilities.
Developed from the reference brands Elvanse/Vyvanse, this product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Lisdexamfetamine INN had a total global sales of $6.1bn in 2023, with a 3Y CAGR of 10%, according to IQVIA.
Building on this success, Adalvo is preparing to launch Lisdexamfetamine Oral Solution across multiple countries in the near future. This value-added formulation will offer greater flexibility in treatment options, further enhancing our portfolio and expanding patient access to tailored ADHD treatments globally.
This achievement reflects Adalvo’s ongoing commitment to operational excellence and strategic growth.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!